目的:比较分析核基质蛋白22(NMP22)和尿细胞学(UC)在膀胱癌诊断中的诊断效能。
方法:检索1999年至6月发表的关于NMP22和尿细胞学诊断膀胱肿瘤的中英文研究,进行质量评估,数据提取和分析。
结果:共检索到相关文章397篇,经过筛选,最终纳入了12篇文章,包括2456个科目。异质性测试表明,没有明显的阈值效应。根据随机效应模型进行荟萃分析。结果显示,NMP22和UC的总敏感性为0.79(95%CI[0.73,0.84])(CI:置信区间),0.55(95%CI[0.41,0.69]),和总特异性0.59(95%CI[0.46],分别,0.71),0.91(95%CI(0.81,0.96]),+LR1.9(95%CI[1.4,2.6])(+LR:正似然比),5.9(95%CI[3.3,10.6]),-LR0.35(-LR:负似然比),分别(95%CI[0.27,0.47]),0.49(95%CI[0.38,0.64]),诊断优势比5(95%CI[3,9]),12(95%CI[7,21])。总受试者工作特征曲线下面积(AUC)为0.79(95%CI[0.75,0.82])和0.81(95%CI[0.77,0.84]),分别。
结论:NMP22对膀胱癌具有中等诊断效率。其灵敏度大于UC,但其特异性显著低于UC。目前,它不能取代传统的膀胱镜检查和UC,但它可以结合起来检测膀胱肿瘤。它在筛查中起着重要作用,术后监测和随访。
OBJECTIVE: To compare and analyze the diagnostic efficacy of nuclear matrix protein 22 (NMP22) and urine cytology (UC) in the diagnosis of bladder cancer.
METHODS: Search the Chinese and English studies on NMP22 and urinary cytology in the diagnosis of bladder tumors published between 1999 and June, and conduct quality evaluation, data extraction and analysis.
RESULTS: A total of 397 related articles were retrieved, and 12 articles were finally included after screening, including 2456 subjects. The heterogeneity test shows that there is no discernible threshold effect. Perform meta-analysis according to the random effects model. The results showed that the total sensitivity of NMP22 and UC were 0.79 (95% CI [0.73, 0.84]) (CI: Confidence interval), 0.55 (95% CI [0.41, 0.69]), and the total specificity 0.59 (95% CI [0.46], respectively, 0.71), 0.91 (95% CI (0.81, 0.96]), +LR 1.9 (95% CI [1.4, 2.6]) (+LR: positive likelihood ration), 5.9 (95% CI [3.3, 10.6]), -LR 0.35 (-LR: negative likelihood ration), respectively (95% CI [0.27, 0.47]), 0.49 (95% CI [0.38, 0.64]), diagnostic odds ratios 5 (95% CI [3, 9]), 12 (95% CI [7, 21]). The area under the summary receiver operating characteristics curve (AUC) was 0.79 (95% CI [0.75, 0.82]) and 0.81 (95% CI [0.77, 0.84]), respectively.
CONCLUSIONS: NMP22 has moderate diagnostic efficiency for bladder cancer. Its sensitivity is greater than UC, but its specificity is significantly lower than that of UC. At present, it cannot replace traditional cystoscopy and UC, but it can be combined to detect bladder tumors. It plays a major role in screening, postoperative monitoring and follow-up.